RVM-V001 30 µg

BIOLOGICAL2 trials

Sponsors

RVAC Medicines (US), Inc.

Conditions

COVID-19Infectious Disease

Phase 1

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

TerminatedNCT05420077

RVAC Medicines (US), Inc.COVID-19, Infectious Disease

Start: 2022-09-12End: 2023-06-02Updated: 2023-06-27

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals

TerminatedNCT05788185

RVAC Medicines (US), Inc.COVID-19, Infectious Disease

Start: 2023-03-22End: 2023-09-21Updated: 2023-10-16